GILD Jan 2026 75.000 put
- Business Wire
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
SANTA MONICA, Calif., June 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus® (brexucabtagene autoleucel) at the 2024 European Hematology Association (EHA) Annual Co
- Zacks
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
The latest trading day saw Gilead Sciences (GILD) settling at $63.56, representing a -1.21% change from its previous close.
- ACCESSWIRE
How Luciana Preger Is Helping Advance Gilead’s Work in Oncology
NORTHAMPTON, MA / ACCESSWIRE / June 12, 2024 / Gilead Sciences Luciana Preger credits being exposed to her father's work at a young age with helping inform her own career in medicine. Luciana is a physician with more than 20 years of experience in ...
